Current Research and Development Status of Chimeric Antigen Receptor (CAR) T-Cell Therapy Market
상품코드:1691626
리서치사:BCC Research
발행일:2025년 03월
페이지 정보:영문 160 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 키메라 항원 수용체(CAR) T 세포 치료 시장 규모는 2024년 46억 달러에서 예측 기간 동안 40.2%의 CAGR(연평균 성장률)을 기록하며 2029년 말에는 251억 달러에 달할 것으로 예상됩니다.
Yescarta 시장 규모는 2024년 18억 달러에서 예측 기간 동안 36.7%의 CAGR로 2029년 말에는 87억 달러에 달할 것으로 예상되며, Carvykti 시장 규모는 2024년 7억 1,000만 달러에서 2029년 말에는 52.6%의 CAGR로 59억 달러에 달할 것으로 예상됩니다.
세계의 키메라 항원 수용체(CAR) T 세포 치료 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 법·규제 환경, 신흥 기술 및 기술 개발 동향, 시장 규모 추정과 예측, 각종 부문별·지역별 상세 분석, 경쟁 구도, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.
목차
제1장 주요 요약
시장 전망
조사 범위
시장 요약
제2장 시장 개요
개요
시장과 기술 배경
CAR-T 세포 치료 발전 경위
FDA 제품 승인
기타 CAR-T 세포 치료
CAR-T 세포 치료 임상 응용
양자 세포 이식(ACT) 기술
제3장 시장 역학
시장 역학
시장 성장 촉진요인
암 발생률 증가
CAR-T 세포 치료 연구에 대한 투자와 자금 증가
강력한 연구개발 파이프라인
유전자 공학의 진보
시장 성장 억제요인
복잡한 법 및 규제 절차
경쟁 대체 제품
시장 기회
정밀의료의 중요성 상승
CAR-T 세포 치료 응용 범위 확대
시장 과제
복잡한 제조와 공급망
CAR-T 세포 치료 상환 과제
제4장 신기술과 임상시험
세계에서 행해지고 있는 임상시험
중국의 CAR-T 세포 임상시험 분포
제5장 시장 세분화 분석
중요한 포인트
세분화 내역
세계의 CAR-T 세포 치료 시장 : 제품별
Yescarta
Kymriah
Tecartus
Abecma
Breyanzi
Carvykti
세계의 CAR-T 세포 치료 시장 : 적응증별
지역적 내역
세계의 CAR-T 세포 치료 시장 : 지역별
북미
유럽
아시아태평양
기타 지역
제6장 특허 리뷰와 새로운 전개
맞춤형 환자 치료에 관한 특허 소송 증가가 예상
기업 고유의 지적재산·특허 정보
Amgen
Avacta Life Sciences Ltd.
Bluebird Bio
Celgene Corp.
Cellectis
Celyad SA
Editas Medicine Inc.
Eureka Therapeutics Inc.
iCell Gene Therapeutics
Juno Therapeutics Inc.(A Celgene Co.)
Noile-Immune Biotech
Novartis AG
제7장 경쟁 정보
주요 기업의 순위
전략적 고려
제8장 키메라 항원 수용체(CAR) T 세포 치료 시장의 지속가능성 : ESG 관점
ESG : 소개
제약 업계에서 ESG의 역할
ESG 퍼포먼스 분석
환경
사회
거버넌스
ESG 리스크 평가
결론
제9장 부록
조사 방법
약어
참고문헌
기업 개요
ABBVIE INC.
ALLOGENE THERAPEUTICS
AMGEN INC.
ASTRAZENECA
BLUEBIRD BIO INC.
BRISTOL-MYERS SQUIBB CO.
CELLECTIS S.A.
EUREKA THERAPEUTICS INC.
GILEAD SCIENCES INC.
ICELL GENE THERAPEUTICS INC.
JOHNSON & JOHNSON SERVICES INC.
LES LABORATOIRES SERVIER
NOVARTIS AG
PFIZER INC.
PROTHERAGEN INC.
ksm
영문 목차
영문목차
The global market for CAR T-cell therapy is expected to grow from $4.6 billion in 2024 and projected to reach $25.1 billion by the end of 2029, at a compound annual growth rate (CAGR) of 40.2% from 2024 to 2029.
The global CAR T-cell therapy market for Yescarta is expected to grow from $1.8 billion in 2024 and projected to reach $8.7 billion by the end of 2029, at a CAGR of 36.7% from 2024 to 2029.
The global CAR T-cell therapy market for Carvykti is expected to grow from $710 million in 2024 and projected to reach $5.9 billion by the end of 2029, at a CAGR of 52.6% from 2024 to 2029.
Report Scope
This report incorporates an in-depth analysis of CAR T-cell therapy's current R&D status, including market estimations and trends, using 2023 as the base year and forecasting 2024 through 2029 with a compound annual growth rate (CAGR) projection. It provides an overview of the industry structure and its competitive landscape. Leading market players' profiles, product offerings, financial information and recent market activities are provided. This report also assesses companies' business strategies and their effect in the face of the competitive environment. The report details the CAR T-cell therapy market based on products. It reviews the historical development of CAR T-cell technology, ongoing clinical and non-clinical advances in CAR T-cell therapy and regulatory requirements. Regional analysis includes the U.S. and international markets.
Report Includes
14 data tables and 71 additional tables
Overview and analysis of the global markets for chimeric antigen receptor (CAR) T-cell therapy with an emphasis on the current status of R&D
Analyses of global market trends, with revenue data for 2022 and 2023, estimates for 2024, and projected CAGRs through 2029
Estimates of the market size and revenue growth prospects for the global CAR T-cell therapy market, along with a market share analysis by product, application, technology type and region
Facts and figures pertaining to the market dynamics, technological advances, product innovations, regulatory landscape, clinical trials, research and business consolidations, and the impact of macroeconomic factors
Insights derived from the Porter's Five Forces model, as well as global supply chain and PESTLE analyses
Assessment of current marketed drugs, including drug development activity, R&D activity and anticipated developments, along with a look into the patent expirations in the industry
An analysis of patents, emerging trends and developments in the industry
Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies
Analysis of the industry structure, including companies' market shares and rankings, strategic alliances, M&A activity and a venture funding outlook
Profiles of leading companies, including Novartis AG, Bristol Myers Squibb Co., Gilead Sciences Inc., Johnson & Johnson Services Inc., and AstraZeneca
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Market and Technology Background
A Brief History of CAR T-Cell Therapy
FDA Product Approvals
Other CAR T-Cell Therapies
Clinical Applications of CAR T-Cell Therapy
Adoptive Cell Transfer (ACT) Technologies
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Increasing Incidence of Cancer
Growing Investments and Funding in CAR T-Cell Therapy Research
Robust R&D Pipeline
Advances in Genetic Engineering
Market Restraints
Complex Legislative and Regulatory Procedures
Alternative Products from Competitors
Market Opportunities
Growing Significance of Precision Medicine
Expanding Applications for CAR T-Cell Therapy
Market Challenges
Complex Manufacturing and Supply Chain
Reimbursement Challenges for CAR T-Cell Therapy
Chapter 4 Emerging Technologies and Clinical Trials
Introduction
Clinical Trials Being Conducted Globally
Distribution of CAR T-Cell Clinical Trials in China
Chapter 5 Market Segmentation Analysis
Key Takeaways
Segmentation Breakdown
Global Market for CAR T-Cell Therapy, by Product
Yescarta
Kymriah
Tecartus
Abecma
Breyanzi
Carvykti
Global Market for CAR T-Cell Therapy, by Indication
Geographic Breakdown
Global Market for CAR T-Cell Therapy, by Region
North America
Europe
Asia-Pacific
Rest of the World
Chapter 6 Patent Review and New Developments
Introduction
Anticipated Increase in Patent Litigation on Customized Patient Treatments
Company-specific Intellectual Property and Patent Information
Amgen
Avacta Life Sciences Ltd.
Bluebird Bio
Celgene Corp.
Cellectis
Celyad SA
Editas Medicine Inc.
Eureka Therapeutics Inc.
iCell Gene Therapeutics
Juno Therapeutics Inc. (A Celgene Co.)
Noile-Immune Biotech
Novartis AG
Chapter 7 Competitive Intelligence
Ranking of Leading Players
Strategic Considerations
Chapter 8 Sustainability in the CAR T-Cell Therapy Market: ESG Perspective
